IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
|
|
- Frederica Ball
- 5 years ago
- Views:
Transcription
1 IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and UC New targets and new drugs IBD management journey Induction of remission Maintenance of remission Maintenance of remission off steroids and / or mucosal healing (histology)
2 Impact of Vitamin D on Risk for Surgery and Hospitalization in IBD One-third of patients were deficient (25[OH]D <2 ng/ml) and 27% were insufficient In CD patients, plasma 25[OH]D <2 ng/ml was associated with: Increased risk for surgery (OR 1.76; 95% CI ) Increased risk for hospitalization (OR 2.7; 95% CI ) Similar associations were seen for UC In CD patients, normalization of vitamin D status was associated with reduced likelihood of surgery (OR.48; 95% CI.32-.7) and hospitalization (OR.51; 95% CI ) Normalization of vitamin D status was associated with lower median CRP levels Ananthakrishnan AN et al. Abstract Budesonide MMX for UC: Primary Endpoint Combined Clinical and Endoscopic Remission 2 * ** *** % of Patients N=12 N=8 1 9 Asa.= Asacol Ent.= Entocort B-MMX= Budesonide MMX N=21 N=12 3 N=1 9 N=23 2 N=121 N=19 N=23 N=124 N=13 Placebo B-MMX 9 mg B-MMX 6 mg Asa./Ent. Sandborn WJ et al. Gastroenterology 212 Nov;143(5): Travis,S et al. Gut. 213 Feb 22. *p=.143 **p=.47 ***p=.2 Biologics, combo therapy and other management issues Anti-TNFs in UC Infliximab versus Cyclo Post-op prevention of CD Discontinuing biologics
3 Biologics in IBD Infliximab cover Gastro 1995; NEJM 1997 (ca2) Adalimumab for Crohn s disease (22) Certolizumab Pegol for Crohn s disease (28) Adalimumab for UC (212) Infliximab approved for Crohn s disease 1998 Infliximab for ulcerative colitis (25) Natalizumab for Crohn s disease (28) Golimumab for UC (213) SONIC Clinical Remission Without Corticosteroids at Week 26 Primary Endpoint Proportion of Patients (%) 1 p<.1 8 p=.9 p= /17 75/169 96/169 AZA + placebo IFX + placebo IFX+ AZA Colombel, J.F., et al., N Engl J Med. 362(15): p IBD has common genetic origins NOD2 PTPN22 CD genes 3 CD specific loci 11 IBD loci Common pathways: Leprosy Mycobacterial susceptibility Other immunemediated disease UC genes 23 UC specific loci MHC Genes in common Jostins, L. et al. Nature 491, (1 November 212)
4 UC SUCCESS Moderate-to-severe UC failing steroids Naive to azathioprine or had stopped 3 months prior to entry Excluded intermediate TPMT activity AZA 2.5mg/kg IFX 5mg/kg IFX + AZA 1 endpoint: Steroid-free remission at week 16 (total Mayo score 2) 2 endpoint: mucosal healing Panaccione R et al. DDW 211; Abstract 835 UC SUCCESS study Patients (%) * *P<.5 compared to IFX; #P<.5 compared to AZA Panaccione R et al. DDW 211; Abstract 835 Adalimumab in UC 4% of patients in trial were previously anti TNF exposed Week 8 Week 52 Weeks 8 and 52 P< P= Placebo Adalimumab (n=248) Patients (%) P= P< P< P<.1 25 P<.5 P< P= Sandborn WJ et al. Gastroenterology. 212 Feb;142(2):257-65
5 Proportion of patients (%) Golimumab in UC (PURSUIT-SC): Clinical Response at Week 6 Randomized Patients in Phase p<.1 p< * * Placebo (n=256) 2 mg 1 mg (n=257) 4 mg 2 mg (n=258) Defined as a decrease from baseline in the Mayo score by 3% and 3 points, with either a decrease from baseline in the rectal bleeding subscore of 1 or a rectal bleeding subscore of or 1 W Sandborn et al. Gastroenterology. 213 Jun 1. Golimumab in UC (PURSUIT-SC): Maintenance of Clinical Response Through Week 54 Proportion of patients (%) Randomized Patients in Clinical Response to Golimumab Induction 31.4 Placebo (n=156) p=.1 p<.1 Defined as a decrease from Week of the induction studies in the Mayo score by 3% and 3 points, with either a decrease from baseline in the rectal bleeding subscore of 1 or a rectal bleeding subscore of or GLM 5 mg (n=153) 5.6 GLM 1 mg (n=154) Rutgeerts P, et al. UEGW 212 CsA vs IFX in IV Steroid- Refractory UC: The CYSIF Study Colectomy-free survival Time to Colectomy p=.66 Day 7 response rates: CsA = 84%; IFX = 86% (P=.76) Colectomy rate Cys: 18 ± 5% (n=1) IFX: 21± 5% (n=13) CsA n=55 IFX n= Days since randomisation % of patients at risk Laharie D et al. Lancet. 212 Dec 1;38(9857):
6 Comparative Efficacy of Adalimumab vs Immunomodulators and 5-ASA in Preventing Postoperative Recurrence of CD Patients (N=51) with CD who had undergone ileocolonic resection Randomized to receive adalimumab, azathioprine, or mesalamine 2 weeks after surgery Patients followed for 2 years Quality of life higher in adalimumab group Savarino E et al. Abstract 92 Genoa Italy Can we ever stop biologics? Usually continue indefinitely but may be subset of patients on immunomodulators that can stop Maintaining remission on antimetabolites after stopping infliximab in Crohn s disease: a prospective cohort study STORI Kaplan-Meier Curve of Relapse n=52 relapses/115 patients Median follow-up 28+/- 2 months Median time to relapse: 16.4 months Louis E, et al. Gastroenterology. 212 Jan;142(1):63-7
7 Predictive Model for Time-to-Relapse Kaplan Meier time-to-relapse curves according to multivariate models and scores generated through Cox model using multiple imputations Proportion without relapse Deleterious factors were: No previous surgery method No. of deleterious factors 1..8 < > Months since infliximab withdrawal Steroid use within 12-6 months before infliximab withdrawal Male gender Haemoglobin 14.5 g/dl Louis E, et al. Gastroenterology. 212 Jan;142(1):63-7 leukocyte count >6 1 9 /l hscrp 5 mg/l faecal calprotectin 3 µg/g CDEIS > infliximab trough 2 mg/l Tools for guiding therapy Emerging concept: more inflammation requires more anti-tnf Higher drug levels correlate with mucosal healing Clinical Outcomes at >52 Weeks According to Trough Infliximab Concentration Clinical Remission C-reactive Protein Endoscopic Change *P<.1 * *P<.1 *P<.1 * * Undetectable 2. ug/ml Undetectable 2. ug/ml Undetectable 2. ug/ml Maser EA et al. Clin Gastroenterol Hepatol. 26;4:
8 SONIC: IFX Trough Levels at Week 3* are Higher with Concomitant AZA Median Serum Trough Levels (mg/ml) (N=97) (N=19) * Patients who had 1 or more PK samples obtained after their first study agent administration were included in the analysis Sandborn, W. et al. NEJM, 21 Trough Concentration of Infliximab is Higher With Concurrent Methotrexate 6.35 Infliximab plus µg/l 3.75 Feagan B et al. DDW 28. Abs no. 682C. Benefit of Immunomodulators with anti-tnf on Antibody Formation Infliximab 1 (CD 5 mg/kg) (CD 1 mg/kg) Infliximab 2 (UC 5 mg/kg) (UC 1 mg/kg) Patients, % Episodic Maintenance Scheduled Maintenance IMS- IMS+ IMS- IMS+ 38% 16% 11% 8% 7% 4% No data 19% 9% 2% 4% Certolizumab 3 (PRECiSE I) 1% 4% Certolizumab 4 (PRECiSE II) 24% 8% 12% 2% Adalimumab 5 (RA, all doses) 12% 1% No data Adalimumab 6 (CLASSIC II) 4% % IMS, immunosuppressant; RA, rheumatoid arthritis; UC, ulcerative colitis 1. Hanauer et al. Clin Gastroenterol Hepatol. 24;2(7): Sandborn WJ, et al. Presented at DDW; May 19 24, 27. Abstract T Sandborn WJ, et al. N Engl J Med. 27;357: Schreiber S, et al. N Engl J Med. 27;357: Summary of Product Characteristics for adalimumab. Abbott Laboratories. July Sandborn WJ, et al. Gut. 27;56:1232.
9 Detectable Serum Trough IFX Concentration is Associated with Higher Remission Rate and Endoscopic Improvement in UC Patients % of patients P<.1 Undetectable serum IFX predicted an increased risk for colectomy (55% vs 7%; p<.1) Seow CH et al. Gut 21;59:49-54 Adalimumab in UC: Remission associated with higher adalimumab levels Sandborn WJ, et al Gastro 212;142:257 Management of Secondary Infliximab Failure Based on Serum Levels of Infliximab and Antibodies to Infiximab Patients with secondary infliximab failure (N=46) randomized to infliximab q4w or interventions based on combined infliximab and anti-infliximab serum concentrations Patients with anti-infliximab antibodies and low infliximab levels switched to adalimumab Patients without anti-infliximab antibodies and low infliximab levels were dose escalated Response rate 58% in algorithm group vs 53% in dose-escalation group v Algorithm p=.13 IFX q4 p<.1 p<.1 Steenholdt C et al. Abstract 94
10 Methods Prevalence and Impact of Antibodies to Adalimumab (UCSF) Antibodies to adalimumab (ATA), serum levels of adalimumab, symptoms, and CRP levels measured in 54 female IBD patients (2 with UC) Results Prevalence of detectable ATA was 22.2% Prevalence of detectable adalimumab concentration was 9.7% Serum concentration of <5 µg/ml of adalimumab associated with elevated CRP More active disease demonstrated in patients with low drug concentrations (<5 µg/ml) and/or detectable ATA (P=.1) Velayos FS et al. Abstract 49 Adalimumab levels correlate with mucosal healing Yarur AJ et al. Abstract Tu1147 Is Fecal Loss of Infliximab a Cause of Lack of Response to Treatment? Background Infliximab may be lost through leaky gut that is characteristic of the denuded and ulcerated mucosa in severe CD and UC Methods Repeated fecal samples collected from IBD patients within first 14 days of therapy Infliximab levels quantified in samples Patients Severe IBD (N=9; 3 with CD, 6 with UC) Results Infliximab could be detected in the feces of all patients Highest concentrations were measured in the first days after initiation of therapy In nonresponders (3/9), the amount of drug detected in the stool at the first day after infusion was significantly higher than in patients who had a clinical response (P=.24) Conclusion Non-response to infliximab associated with rapid clearance through stool (and high inflammatory burden) Brandse JF et al. Abstract 157
11 New targets and treatments SONIC: Corticosteroid-Free Clinical Remission at Week 26 Proportion of Patients (%) Primary Endpoint P<.1 P=.6 P= % 52/17 75/169 96/169 AZA + placebo IFX + placebo IFX+ AZA Colombel J-F et al. N Engl J Med. 21 Apr 15;362(15): Ustekinumab for Crohn s disease: blocks IL-12/IL Clinical Response and Remission at Weeks 6 and 8 Placebo UST 1 mg/kg UST 3 mg/kg UST 6 mg/kg UST combined 2 1 Clinical Response Week 6 Clinical Response Week 8 Clinical Remission Week 6 Clinical Remission Week 8 (primary end point) *P<.5 Sandborn W, et al. N Engl J Med. 212 Oct 18;367(16):
12 Vedomizumab in UC: Clinical Response, Remission, Mucosal Healing at 6 Weeks % P< % CI: 11.6, 31.7 Feagan B, et al. DDW212 Induction ITT Population Placebo Vedolizumab P= P= Clinical Response Clinical Remission Mucosal Healing , , % Vedolizumab in UC: Primary and Secondary Outcomes Through 52 Weeks, Maintenance ITT Population 15.9 *** *** Clinical Response 23.8 *** 56.6 *** 56. *** 52. *** 51.6 Durable Clinical Response 19.8 Mucosal Healing 8.7 ** ** Durable Clinical Remission 13.9 Placebo VDZ Q8 wks VDZ Q4 wks * 31.4 *** 45.2 CS Free Remissions n: *P<.5 **P<.1 ***P<.1 Feagan B, et al. DDW212 Janus Kinase Pathway Janus kinase inhibitor Targets a specific intracellular signaling cascade-jak/stat pathway The JAK family binds multiple cytokine receptors including: IL2/IL4/IL7/IL9/IL12 (JAK3) IFNs Tofacitinib is JAK3 inhibitor used for psoriasis and rheumatoid arthritis. TNF, tumor necrosis factor; RA, rheumatoid arthritis Shuai K et al. Nat Rev Immunol. 23;11:9.
13 Phase 2 Study of Tofacitinib (CP-69,55), an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis Week 8 Sandborn W et al. N Engl J Med 212 Positioning New and Established Medications for IBD Induction of Remission/ Active Disease Maintenance of Remission Cyclosporine Vedolizumab Ustekinumab (CD) Anti-TNFs Tofacitinib Corticosteroids Vedolizumab Anti-TNFs MTX 6-MP/AZA
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationWhen can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
When can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Post-op low risk patient Uc de-escalation Discuss combo therapy Which one worked IBD
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationNew Perspectives on the Diagnosis and Management of IBD. Disclosures
New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationCurrent and Emerging Biologics for Ulcerative Colitis
Gut and Liver, Vol. 9, No. 1, January 2015, pp. 18-27 Review Current and Emerging Biologics for Ulcerative Colitis Sung Chul Park* and Yoon Tae Jeen *Division of Gastroenterology and Hepatology, Department
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationCase Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis Kerry Jo Lee, MD Medical Officer Division of Gastroenterology and Inborn Error Products Office of New
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More information